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Abstract
Background: The peptide hormone calcitonin (CT) can significantly effect the proliferation rate
of CT receptor (CTR) positive human cancer cells. We wish to identify additional human cancers
expressing CTRs and assay the effects of CT on their growth rates and signal transduction
pathways.
Results:  The expression of the human calcitonin receptor (hCTR) gene in the chronic
myelogenous leukemia cell line K562 was examined. RT-PCR on total RNA extracted from K562
cells detected the presence of hCTR mRNA. Further analysis demonstrated that multiple hCTR
isoforms were present. Incubation of K562 cells with salmon calcitonin (sCT), but not amylin,
caused an increase in intracellular levels of cAMP similar to that induced by forskolin treatment.
We further demonstrated that butyrate induced erythroid differentiation of K562 cells caused a
significant decrease in hCTR mRNA levels. However, phorbol myristate acetate (PMA) induced
megakaryocytic differentiation of these cells had no significant effect on hCTR mRNA levels. We
demonstrated that exposure to various concentrations of sCT had no effect on the cellular
proliferation of K562 cells in vitro.
Conclusion: Chronic myelogenous k562 cells express multiple CTR isoforms. However, CT does
not effect K562 proliferation rates. It is likely that the small increase in intracellular levels of cAMP
following CT treatment is not sufficient to interfere with cellular growth.
Background
The hypocalcemic hormone calcitonin (CT), first identi-
fied by Copp et al. [1], is produced by the parafollicular
cells of the thyroid gland in response to increases in extra-
cellular levels of calcium. CT regulates serum calcium lev-
els by inhibiting osteoclast mediated bone resorption and
enhancing calcium excretion by the kidney [2–4]. Howev-
er, the presence of non-thyroidal forms of CT in tissues
such as the central nervous system and prostate suggests it
may play a role in other physiological processes [5,6]. The
hypocalcemic effects of CT are mediated by high affinity
CT receptors (CTRs). The CTR is a member of a subfamily
of the seven trans-membrane domain G protein-coupled
receptor superfamily that includes glucagon-like peptide 1
[7], glucagon [8], pituitary adenylate cyclase-activating
polypeptide [9], corticotropin-releasing factor [10], gastric
inhibitory polypeptide receptors [11] and PTH/PTH-relat-
ed peptide [12]. CTRs have been identified in a variety of
tissues such as skeletal muscle [13], kidney [14,15], oste-
oclasts [16,17] and spermatozoa [18]. Through the use
transgenic mouse technology we recently identified a vari-
ety of novel, developmentally regulated sites of CTR gene
Published: 25 April 2003
Cancer Cell International 2003, 3:6
Received: 19 February 2003
Accepted: 25 April 2003
This article is available from: http://www.cancerci.com/content/3/1/6
© 2003 Mould and Pondel; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in 
all media for any purpose, provided this notice is preserved along with the article's original URL.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/6
Page 2 of 7
(page number not for citation purposes)
expression [19]. Studies have also demonstrated that
breast cancer cell lines and primary breast tumors also ex-
press high levels of CTRs [20–22]. CT induces a marked
growth inhibition of these cells in vitro [23]. It would be
of clinical interest to identify other human cancers that ex-
press CTRs as they may play a role in the differentiation
and growth of these cells in vivo.
In this report, we identified the expression of CTRs in the
human chronic myelogenous leukemia cell line K562. RT-
PCR analysis revealed the presence of multiple hCTR iso-
forms. Butyrate induced erythroid differentiation of these
cells caused a significant reduction in the expression of
CTR mRNA. In contrast, PMA induced megakaryocytic dif-
ferentiation of K562 cells had no effect on hCTR mRNA
levels. We further demonstrated that CT, but not amylin,
induced an increase in intracellular levels of cAMP of
these cells. Finally, we demonstrated that CT did not sig-
nificantly suppress cellular proliferation of K562 cells in
vitro.
Results
CTR mRNA in K562 cells
Ongoing research in our laboratory detected the presence
of a tissue specific factor associated with hCTR gene ex-
pression in K562 cells (G. Partington, unpublished re-
sults). We therefore wished to determine if the hCTR gene
was transcriptionally active in K562 cells. RT-PCR was per-
formed on K562 total RNA employing oligonucleotides
that would enable us to detect the three most common
hCTR isoforms, hCTR1a, hCTR1b and hCTR1a truncated
[26–28]. Ethidium bromide staining of the RT-PCR prod-
ucts revealed two poorly resolved bands differing in size
by approximately 50 bp (data not shown). This suggested
the presence of two hCTR isoforms. It was likely that these
products corresponded to hCTR1a and hCTR1b, previously
shown to differ in size by a 16 amino acid insert present
in hCTR's first intracellular loop [27,28]. While a 32P end
labelled hCTR specific probe hybridized to the RT-PCR
products, it was unable to resolve both isoforms (Fig. 1).
We therefore carried out RT-PCR again, separated and pu-
rified the bands from a 2% agarose gel followed by addi-
tional electrophoresis and Southern blotting. The blot was
hybridized with the same hCTR probe. Autoradiography
demonstrated the presence of two CTR positive bands dif-
fering in size by approximately 50 bp (Fig. 2A). When the
blot was stripped and re-hybridized with a probe corre-
sponding to the 16 amino acid insert, only hybridization
to the RT-PCR product in lane 1 was evident (Fig. 2B).
These data suggest that K562's express two of the three
known hCTR mRNA isoforms hCTR1a and hCTR1b.
Butyrate and PMA treatment of K562's
It is well known that K562 cells undergo erythroid differ-
entiation when treated with butyrate [29] whereas treat-
ment with PMA induces megakaryocyte differentiation
[30]. We wished to determine the effect these treatments
had on the expression of hCTR mRNA. K562 cells were in-
cubated with either butyrate or PMA for a period of 48
hours followed by isolation of RNA and semi-quantitative
RT-PCR analysis. Results indicated that treatment with 2
mM sodium butyrate caused a 5–6 fold reduction (as
measured by densitometry) in hCTR mRNA. This suggests
that erythroid differentiation represses hCTR gene expres-
sion in K562 cells. In contrast, megakaryocytic induced
differentiation with 100 nM PMA had no significant effect
on hCTR gene expression (Fig. 3).
Figure 1
Southern blot analysis of RT-PCR products. RT-PCR and no RT controls were carried out on total RNA from K562 cells, 
T47D (hCTR positive) and 3T3 (hCTR negative) cells employing hCTR and actin specific oligos. PCR products were size frac-
tionated on a 1 % agarose gel and Southern blotted. hCTR and actin specific 32P end labelled probes were hybridized to blot. 
These results are representative of 3 independent experiments all giving similar results.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/6
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Effect of sCT and amylin on intracellular levels of cAMP in 
K562 cells
It has been demonstrated that the binding of sCT to the
hCTR causes a significant increase in intracellular levels of
cAMP [27,28]. We therefore assayed the effect of various
concentrations of sCT on intracellular levels of cAMP in
K562 cells. Treatment of K562 cells with 1.0–10 nM sCT
for 20 minutes caused at least a two-fold rise in intracellu-
lar concentrations of cAMP. The effect of sCT on intracel-
lular levels of cAMP was similar to that induced by
treatment with 10 µM forskolin, a known activator of in-
tracellular cAMP (Fig. 4).
Receptor activity modifying protein (RAMP) 1 and 3 can
convert the hCTR into an amylin receptor which when
bound to amylin, another CT related peptide hormone,
increases intracellular levels of cAMP [31]. We therefore
determined the effect of varying concentrations of amylin
on intracellular levels of cAMP in K562 cells. In contrast
to sCT, we were unable to detect any increase in intracel-
lular levels of cAMP following amylin treatment.
Effect of sCT on K562 cellular proliferation
sCT has been found to inhibit the cellular proliferation of
hCTR-positive T47D and MCF7 human breast cancer cells
in vitro while increasing cellular proliferation of hCTR-
positive prostate cancer cells [23,32]. We therefore wished
to determine the effect of sCT, at various concentrations,
on the proliferation of K562 cells in vitro. Results of cell
counts over a 4 day period indicated no effect of sCT, at
any concentration, on cellular proliferation (Fig. 5).
Discussion
CTRs have been reported in a number of human cancer
cell lines including those of lung [33], prostate [32] and
Figure 2
Southern blot analysis on gel purified K562 RT-PCR prod-
ucts. (A) RT-PCR products on total RNA from K562 cells 
employing hCTR specific primers were size fractionated on a 
2% agarose gel. Two bands, corresponding in size to hCTR1a 
and hCTR1b, were individually purified and re-run on a 2% 
agarose gel followed by Southern blot analysis. The blot was 
hybridized with a 32P end-labelled probe common to hCTR1a 
and hCTR1b. (B) Blot in Fig. 2A was stripped of probe and 
re-hybridized with a 32P end-labelled probe corresponding to 
16 amino acid insert in hCTR1b isoform. These results are 
representative of 2 independent experiments giving similar 
results.
Figure 3
Semi-quantitative RT-PCR analysis on butyrate and PMA 
treated K562 cells. Total RNA from butyrate, PMA and 
untreated K562 cells was reverse transcribed and subjected 
to 30, 35 and 40 cycles of PCR employing actin and hCTR 
specific oligos. Reaction products were size fractionated on 
an agarose gel and Southern blotted employing 32P end 
labelled hCTR and actin specific probes. These results are 
representative of 3 independent experiments giving similar 
results.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/6
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breast cancer origin [21,22]. Since studies have
demonstrated that CT can modulate the growth of these
cells it is of clinical interest to identify other human can-
cers that express CTRs. In this study, we demonstrate that
the hCTR gene is transcriptionally active in the chronic
myelogenous leukemia (CML) cell line K562. The K562
line was originally established by Lozzio and Lozzio [34]
from the pleural effusion of a patient with chronic myel-
ogenous leukemia. This cell line is considered to represent
an early differentiation stage of the granulocyte lineage.
The results of our RT-PCR experiments suggest that K562
cells express two of the three known hCTR isoforms. The
most common of these isoforms and present in K562, is
hCTR1a [27,28]. The insert positive hCTR1b, also present
in K562 cells, is expressed in fewer tissue types [27,28].
Both of these isoforms increase intracellular levels of
cAMP when bound to CT. Our result demonstrating that
sCT increases intracellular levels of cAMP in K562 cells is
consistent with these studies. However, sCT does not in-
crease cAMP levels to the extent reported in other CTR
positive cell lines (3–4 fold) such as T47D and MCF7 [20].
Furthermore, our experiments indicate that K562 cells do
not appear to be responsive to amylin. Studies have
shown that receptor activity modifying protein (RAMP) 1
and 3 can convert CTRs into amylin receptors [31]. Amy-
lin receptors like CTRs, activate intracellular levels of
cAMP when bound to amylin. The absence of increased
levels of cAMP in K562 cells following amylin treatment
suggests RAMP 1 and/or 3 are not active/expressed in
these cells. Alternatively, amylin receptors may be present
in K562 cells but our cAMP assay system is not sufficiently
sensitive to detect their activity.
K562 cells are well known to differentiate along an eryth-
roid or megakaryocytic pathway in the presence of bu-
tyrate or PMA, respectively [29,30]. Since nothing is
known about CTR gene expression during erythropoiesis
or megakaryocytic differentiation, we were interested in
Figure 4
Intracellular levels of cAMP in amylin, sCT and forskolin treated K562 cells. K562 cells were treated with varying concentra-
tions of amylin and sCT for 20 minutes followed by analysis of intracellular cAMP levels. Forskolin, a known activator of cAMP, 
was employed as a positive control. Each data point represents an average of 2 assays. These results are representative of 2 
independent experiments each giving similar results.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/6
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determining what effect butyrate and PMA would have on
CTR gene expression in K562 cells. We demonstrate that
CTR gene expression during butyrate induced K562 eryth-
roid differentiation decreases significantly. The role this
down regulation plays is unknown. However, the effects
of forced expression of CTRs in K562 cells combined with
sCT incubation might help to determine the role, if any,
CTRs play in this model system of erythropoiesis. Our re-
sult, demonstrating that the hCTR gene remains transcrip-
tionally active in PMA treated K562 cells, suggests the
possibility that CTRs may be expressed in normal
megakaryocytes. Studies to examine hCTR gene expres-
sion in normal human megakaryocytes are now
underway.
Studies have demonstrated that CT/CTRs can modulate
cellular proliferation [23,32]. Our results clearly demon-
strate that CT, at a variety of concentrations, has no signif-
icant effect on the growth of K562 cells. We hypothesize
this is due to the small effect CT has on increasing intrac-
ellular concentrations of cAMP in K562 cells. Yin et al [35]
demonstrated that forskolin, a known activator of cAMP,
had no effect on the proliferation of K562 cells. They hy-
pothesized that this was due to the inability of forskolin
to increase intracellular levels of cAMP beyond the thresh-
old needed to effect cellular proliferation. We
demonstrate that CT/CTRs have a similar effect on levels
of intracellular cAMP as forskolin in K562 cells. It is likely
that the lack of effect CT has on cellular growth of K562
cells is due to its inability to increase production of cAMP
in these cells to a level necessary to interfere with cellular
proliferation. Interestingly, Yin et al., [35] demonstrated
that a K562 subclone (K/Dau600) showed significantly
high levels of intracellular cAMP in response to forskolin.
Cellular proliferation of this subclone was also inhibited
by forskolin. It would be of interest to determine if CT has
a greater ability to increase intracellular levels of cAMP in
this subclone than in the parental line and subsequently
modulate its proliferation rate.
Conclusions
The results of our study demonstrate that the hCTR gene
is transcriptionally active in K562 CML cells. The expres-
sion hCTR's in this cell line acts to increase intracellular
levels of cAMP when bound to CT. However, CT does not
effect the proliferation rate of these cells. The expression
Figure 5
Cellular proliferation of sCT treated K562 cells. K562 cells were treated with varying concentrations of sCT and assayed daily 
over a four-day period for cell number. Each data point represents an average of four cell counts. These results are represent-
ative of 3 independent experiments each giving similar results.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/6
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of CTR's in K562 cells will prompt future studies to exam-
ine hCTR expression in equivalent cells from patients in
CML blast-crisis. If the hCTR gene is active in these cells,
the effects of CT on their growth and differentiation
should then be assessed.
Methods
Cell Culture
The human chronic myelogenous leukaemia cell line
K562 was obtained from the European Collection of Cell
Cultures. The cells were maintained in RPMI-1640 supple-
mented with 10% fetal calf serum, 100 µg/ml penicillin
and 100 U/ml streptomycin (obtained from Invitrogen).
The CTR positive human breast cancer cell line T47D and
the CTR negative mouse cell line 3T3 were maintained in
DMEM with fetal calf serum and antibiotics as above.
Reverse Transcription and PCR
RT-PCR was carried out on total RNA isolated from the
above cells by acid guanidinium thiocyanate-phenol-
chloroform extraction as described by Chomczynski and
Sacchi [24]. 5 µg of DNase I treated total RNA was reverse-
transcribed in a 25 µl vol. containing 1 × RT Buffer, 1 mM
dNTP's, 250 U M-MLV reverse transcriptase (Gibco BRL)
and 150 ng random primers at 42°C. After one hour, the
reaction mixture was heated to 95°C for 5 minutes. 4 µl
were then employed for PCR amplification of hCTR
mRNA using the following: 200 nM sense primer (TTGCT-
TCTATTGAGCTGTGCC): corresponding to sequences 1–
21 in hCTR complementary DNA (cDNA) and 200 nM
antisense primer (ATGTTCTTGTGCAGGGTTACC):
corresponding to sequences 612–632 in hCTR cDNA, 1 ×
Buffer, 0.2 mM dNTP's and 2 U Amplitaq DNA Polymer-
ase (Roche) in a final volume of 50 µl. Oligonucleotides
were annealed at 58°C for 45 seconds, followed by exten-
sion for 1 minute 30 seconds at 72°C and denaturing at
94°C for 45 sec. In addition, PCR employing a highly
conserved mouse actin sense primer (GTTACCAACT-
GGGACGACATGG): corresponding to 147–168 of the
mouse actin cDNA and a conserved antisense primer
(GATCTTGATCTTCATGGTGC): corresponding to 890–
909 of the mouse actin cDNA was performed, as described
above, on all RNA samples. RT-PCR and no RT reaction
(control) products were size fractionated on a 1 % agarose
gel, excised, purified and run individually on two separate
2% agarose gels followed by Southern blot transfer. Two
32P end-labelled oligonucleotides corresponding to se-
quences 383–405 in human CTR cDNA (present in all
hCTR isoforms) and 494–542 in the "insert positive"
hCTR cDNA, as described by Nakamura et al. [25], were
hybridized to the blots. A highly conserved actin oligonu-
cleotide corresponding to sequences 551–600 in the
mouse actin cDNA was also employed for Southern blot
analysis.
Butyrate and PMA treatment of K562 cells
Erythroid differentiation of K562 cells was induced by the
addition of 2 mM butyric acid (Fluka), neutralised to pH
7.0 with NaOH. Differentiation along the megakaryocytic
pathway was induced by treating cells with 100 nM phor-
bol myristate acetate (PMA), (Alexis). After 48 hours of
treatment, cells were harvested and total RNA isolated as
described above. The RNA samples were reverse tran-
scribed as described above followed by 30, 35 and 40 cy-
cles of PCR. Southern blot analysis of RT-PCR products
was then carried out as described above.
sCT, amylin treatment and levels of K562 intracellular 
cAMP
96-well overnight cultures of K562 cells (seeded at a con-
centration of 105 cells/ml) were treated with sCT or amy-
lin (Bachem) at a concentration of 0 nM, 0.1 nM, 1.0 nM,
10 nM and 100 nM, for 20 minutes at 37°C. As a positive
control for cAMP activation, two wells of cells were treated
with 10 µM forskolin. A Biotrak cAMP enzyme immu-
noassay (EIA) system (Amersham) was used to determine
effects of treatment on intracellular levels of cAMP in
K562 cells.
sCT treatment and cellular proliferation
106 K562 cells were treated with sCT (Bachem) at a con-
centration of 0 nM, 0.1 nM, 1.0 nM, 10 nM and 100 nM
and maintained at 37°C over a period of four days. Cul-
tures were grown it triplicate. Six separate aliquots from
each flask were taken daily and total cell counts were ob-
tained by hemocytometer after staining with toluidine-
blue. Cell media and sCT were changed daily.
Authors' contributions
RM carried out the experiments in this paper. MP con-
ceived and supervised the project.
Acknowledgements
This work was supported by the Wellcome Trust.
References
1. Copp DH, Cameron EC, Cheney BA, Davidson GF and Henze KG
Evidence for calcitonin-A new hormone from the parathy-
roid that lowers blood calcium Endocrinology 1962, 70:638-649
2. Friedman J and Raisz LG Thyrocalcitonin: Inhibitor of bone re-
sorption in tissue culture Science 1965, 150:1465-1467
3. Raisz LG and Nieman I The effects of parathyroid hormone and
thyrocalcitonin on bone in organ culture Nature 1967, 214:486-
487
4. Warshawsky H, Goltzman D, Roeleau MF and Bergeron JM Direct in
vivo demonstration by radioautography of specific binding
sites for calcitonin in skeletal and renal tissues of the rat J Cell
Biol 1980, 85:682-694
5. Fischer JA, Tobler PH, Henke H and Tschopp FA Salmon and hu-
man calcitonin like peptides co-exist in the human thyroid
and brain J Clin Endocrinol Metab 1983, 57:1314-1316
6. Davis NS, DiSant'Agnese PA, Ewing JF and Mooney RA The neu-
roendocrine prostate: characterization and quantitation of
calcitonin in the human gland J Urol 1989, 142:884-888Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/6
Page 7 of 7
(page number not for citation purposes)
7. Thorens B Expression cloning of the pancreatic β cell receptor
for the gluco-incretin hormone glucagon-like peptide 1 Proc
Natl Acad Sci USA 1992, 89:8641-8645
8. Jelinek LJ, Lok S, Rosenberg GB, Smith RA, Grant FJ, Biggs S, Bensch
PA, Kuijper JL, Sheppard PO, Sprecher CA, O'Hara PJ, Foster D,
Walker KM, Chen LHJ, McKernan PA and Kindsvogel W Expression
cloning and signalling properties of the rat glucagon
receptor Science 1993, 259:1614-1616
9. Pisegna JR and Wank SA Molecular cloning and functional ex-
pression of the pituitary adenylate cyclase-activating
polypeptide type 1 receptor Proc Nat Acad Sci USA 1993, 90:6345-
6349
10. Chen R, Lewis KA, Perrin MH and Vale WW Expression cloning
of a human corticotropin-releasing-factor receptor Proc Natl
Acad Sci USA 1993, 90:8967-8971
11. Usdin TB, Mezey E, Button DC, Brownstein MJ and Bonner TI Gas-
tric inhibitory polypeptide receptor, a member of the secre-
tin-vasoactive intestinal peptide receptor family, is widely
distributed in peripheral organs and the brain Endocrinology
1993, 133:2861-2870
12. Juppner H, Abou-Samra AB, Freeman M, Kong XF, Schipani E, Rich-
ards J, Kolakowski LF Jr, Gock J, Pots FT, Dronenberg HM and Segre
GV A G protein-linked receptor for parathyroid hormone
and parathyroid hormone-related peptide  Science 1991,
254:1024-1026
13. Albrandt K, Brady EMG, Moore CX, Mull E, Sierzega ME and Beau-
mont K Molecular cloning and functional expression of a third
isoform of the human calcitonin receptor and partial charac-
terization of the calcitonin receptor gene Endocrinology 1995,
136:5377-5384
14. Lin HY, Harris TL, Flannery MS, Aruffo A, Kaji EH, Gorn A, Kola-
kowski LF, Yamin M, Lodish HF and Goldring SR Expression clon-
ing and characterization of a porcine renal calcitonin
receptor Trans Assoc Am Physicians 1991, CIV:265-272
15. Goldring SR, Dayer DM, Ausiello DA and Krane LM A cell strain
cultured from porcine kidney increases cyclic AMP content
upon exposure to calcitonin or vasopressin Biochem Biophys Res
Commun 1978, 83:434-440
16. Nicholson CG, Mosley JM, Sexton PM, Mendelsohn FAO and Martin
TJ Abundant calcitonin receptors in isolated rat osteoclasts J
Clin Invest 1986, 78:355-360
17. Nicholson CG, Horton MA, Sexton PM, D'Santos CS, Moseley JM,
Kemp BE, Pringle JAS and Martin TJ Calcitonin receptors of hu-
man osteoclastoma Horm Metab Res 1987, 19:585-589
18. Silvestroni L, Menditto A, Frajese G and Gnessi L Identification of
calcitonin receptors in human spermatozoa J Clin Endocrinol
Metab 1987, 65:742-746
19. Jagger C, Chambers T and Pondel M Transgenic mice reveal nov-
el sites of calcitonin receptor gene expression during
development Biochem Biophys Res Comm 2000, 274:124-129
20. Findlay DM, Michelangeli VP, Eisman JA, Frampton RJ, Moseley JM,
MacIntyre I, Whitehead R and Martin TJ Calcitonin and 1,25-dihy-
droxy-vitamin D2 receptors in human breast cancer lines
Cancer Res 1980, 40:4764-4767
21. Martin TJ, Findlay DM, MacIntyre I, Eisman JA, Michelangeli VP, Mos-
ley JM and Partridge NC Calcitonin receptors in a cloned human
breast cancer cell line (MCF-7)  Biochem Biophys Res Commun
1980, 96:150-156
22. Gillespie MT, Thomas RJ, Pu ZY, Zhou H, Martin TJ and Findlay DM
Calcitonin receptors, bone sialoprotein and osteopontin are
expressed in primary breast cancers Int J Cancer 1997, 73:812-
815
23. Ng KW, Liversey SA, Larkins RG and Martin TJ Calcitonin effects
on growth and on selective activation of type II isoenzyme of
cyclic adenosine 3'5'-monophosphate-dependent protein ki-
nase in T47D human breast cancer cells  Cancer Res 1983,
43:794-800
24. Chomczynski P and Sacchi N Single-step method of RNA isola-
tion by acid guanidinium thiocyanate-phenol-chloroform
extraction Anal Biochem 1987, 162:156-159
25. Nakamura M, Hashimoto T, Hakajima T, Ichii S, Furuyama J, Ishira Y
and Kakudo K A new type of human calcitonin receptor iso-
form generated by alternative splicing  Biochem Biophys Res
Commun 1995, 209:744-751
26. Albrandt K, Brady EMG, Moore CX, Mull E, Sierzega ME and Beau-
mont K Molecular cloning and functional expression of a third
isoform of the human calcitonin receptor and partial charac-
terization of the calcitonin receptor gene Endocrinology 1995,
136:5377-5384
27. Moore EE, Kuestner RE, Stoop SD, Grant FJ, Matthews SL, Brady CL,
Sexton PM and Findlay DM Functionally different isoforms of
the human calcitonin receptor result from alternative splic-
ing of the gene transcript Mol Endocrinol 1995, 9:959-967
28. Egerton M, Needham M, Evans S, Millest A, Cerillo G, McPheat J, Pop-
plewell M, Johnstone D and Hollis M Identification of multiple hu-
man calcitonin receptor isoforms: heterologous expression
and pharmacological characterization  J of Mol Endocrinology
1995, 14:179-189
29. Andersson LC, Jokinen M and Gahmberg CG Induction of eryth-
roid differentiation in the human K562 cell line Nature 1979,
278:364-365
30. Tatteroo PA, Massaro F, Mulder A, Schreuder-van Gelder R and Von
dem Borne AE Megakaryoblastic differentiation of proeryth-
roblastic K562 cell line cells Leuk Res 1984, 8:197-206
31. Christopoulos G, Perry K, Morfis M, Tilakaratne N, Gao Y, Main MJ,
Fraser NJ, Foord SM and Sexton PM Multiple amylin receptors
arise from receptor activity modifying protein interactions
with the calcitonin receptor gene product Mol Pharmacol 1999,
56:235-242
32. Shah GV, Rayford W, Noble MJ, Austenfeld M, Weigel J, Vamos S and
Mebust WJ Calcitonin stimulates growth of human prostate
cancer cells through receptor mediated increase in cyclic ad-
enosine 3'5'-monophosphates and cytoplasmic Ca2+  tran-
sients Endocrinology 1994, 134:596-602
33. Findlay DM, DeLuise M, Michelangeli VP, Ellison M and Martin TJ
Properties of a calcitonin receptor and adenylate cyclase in
BEN cells, a human cancer cell line Cancer Res 1980, 40:1311-
1317
34. Lozzio CB and Lozzio BB Human chronic myelogenous leuke-
mia cell-line with positive Philadelphia chromosome  Blood
1975, 45:321-328
35. Yin Y, Allen PD, Jia L, Macey MG, Kelsey SM and Newland AC Con-
stitutive levels of cAMP-dependent protein kinase activity
determine sensitivity of human multidrug-resistant leukae-
mic cell lines to growth inhibition and apoptosis by forskolin
and tumour necrosis factor alpha Brit J of Haem 2000, 108:565-
573